Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

T. S. Larsen*, O. W. Bjerrum, N. Pallisgaard, M. T. Andersen, M. B. Møller, H. C. Hasselbalch

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review


Quantitative assessment of the JAK2 V617F allele burden during disease evolution and ongoing myelosuppressive treatment is likely to be implemented in the future clinical setting. Interferon alpha has demonstrated efficacy in treatment of both chronic myeloid leukemia and the Philadelphia chromosome negative chronic myeloproliferative disorders. Reductions in the JAK2 V617F allele burden in patients treated with pegylated interferon alpha-2a (Peg-IFN-2a) have been demonstrated, although follow-up was relatively short. We report here the first profound and sustained molecular responses with a JAK2 V617F allele burden below 1.0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response.

Original languageEnglish
JournalAnnals of Hematology
Issue number10
Pages (from-to)847-850
Number of pages4
Publication statusPublished - 2008
Externally publishedYes


  • Interferon
  • JAK2
  • PCR
  • Polycythemia vera
  • Remission

Cite this